Replies to post #796 on Biotech Values

[DewDiligence]

Dr. Chaplin has an impressive background indeed, and it’s reassuring to have such a credentialed CSO when the CEO is just a “deal” man.

Speaking of coincidences… it must be a coincidence that you were thinking about your comments in #534 and I just happened to reference that post on the Yahoo OXGN board :-)

Since you read the Yahoo board, perhaps you ought to post over there occasionally. Your insightful and level-headed commentary could help to neutralize the often one-sided character of that board.

[mskatiescarletohara]

Isolution, DEW, Mid-Swe...OXi's patents.

I, too, have pondered about Oxi's IP regarding Combre, and I have wondered what precisely did Oxi license from the University of Arizona. According to the website they hold a worldwide license to Combre's synthetic use from AZ. Is this assumption correct, and if so, who holds the main patent on Combretastin? Is there a major holder of one patent which covers all uses Combretastin? How can AZE and AVE develop their VTAs without potentially infringing on Oxi's patents? Isn't their candidates using the tubulin process too?

There are many VTAs in development, and some companies claim they hold broad patents regarding VTA, there are many doctors who are working in the field which have developed or found specific targets for potential therapies, so if they find a target, do they patent it? There was a time when PPHM and OXGN were partners in developing VTAs, and when they dissolved their partnership there was a division of patents which each company held in respect to their compounds. PPHM's VTA platform targets phosphids, a biologic and OXI's is a synthetic.

Also, the former COO of OXGN, David Sherris, who helped implement OXI's VTA program is now with PPHM preparing their VTA for launch sometime this year. Here is his new website, which might be a good one to monitor in the future.

www.sherrispharma.com

katie...